Clinical Trials

Alexion unveils positive top-line results from phase 3 study of Ultomiris in aHUS

Alexion Pharmaceuticals announced that the Phase 3 study of ULTOMIRIS (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its primary objective in complement inhibitor-naïve patients with atypical hemolytic uremic syndrome (aHUS).

Destiny’s XF-73 meets primary objective in second phase 1 skin irritation study

Destiny Pharma has reported positive data and non-irritant classification for the nasal gel formulation of its synthetic antimicrobial drug XF-73 in the second phase 1 skin irritation study.

Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression

Navitor Pharmaceuticals announced the initiation of Part B of its Phase 1 clinical study with its lead candidate, NV-5138, for treatment-resistant depression (TRD).

Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463

Ironwood Pharmaceuticals announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders.

Redx gets regulatory nod to restart RXC004 clinical trial

Redx has secured approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to restart a phase 1/2a trial for its cancer candidate RXC004 in advanced solid tumors.

Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism

Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced it has initiated dosing in a Phase 2 study for its lead compound, SXC-2023, for the treatment of moderate to severe trichotillomania in adults.

Vaccinex completes enrollment for SIGNAL Huntington’s disease trial

Vaccinex has completed subject enrollment for the SIGNAL trial, which is a phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with early manifest and late prodromal Huntington’s disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 (pepinemab).

ADC doses first patient in phase I trial of ADCT-601 in advanced solid tumors

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic.

hVIVO achieves primary endpoint in phase II vaccine flu study

hVIVO has announced positive result for the primary endpoint, following completion of analysis of samples by NIAID and additional results from the Phase IIb viral challenge study of FLU-v, (Study 004, NCT03180801).